The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.
N. Sinclair
No relevant relationships to disclose
M. M. Abu-Khalaf
No relevant relationships to disclose
B. J. Sakr
No relevant relationships to disclose
T. Rizack
No relevant relationships to disclose
D. R. Lannin
No relevant relationships to disclose
J. S. Gass
No relevant relationships to disclose
R. Strenger
No relevant relationships to disclose
V. Bossuyt
No relevant relationships to disclose
M. A. Fenton
No relevant relationships to disclose
L. Harris
No relevant relationships to disclose
W. M. Sikov
Research Funding - Abraxis BioScience